Outset Medical Inc. has announced new research findings from over 1 million Tablo hemodialysis treatments across approximately 750 facilities, as well as 5-year results from the insourcing of dialysis at a large hospital in Florida. The findings will be presented at the American Society of Nephrology's Kidney Week 2025, taking place November 5-8 in Houston. Highlights include a reported 94% reduction in serious cardiac or respiratory events, a sustained reduction in central-line bloodstream infections, a high nurse retention rate with more than 95% dialysis staff satisfaction, and a strong return on investment within the first two years at the AdventHealth Ocala, Florida site. Additional data from 10,000 treatments performed at approximately 150 hospitals showed over 99% achievement of treatment goals for extended dialysis sessions, with minimal interruptions and rapid resolution of treatment alarms.